Heron Therapeutics (HRTX) News Today $2.31 +0.02 (+0.87%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$2.34 +0.03 (+1.26%) As of 03/27/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Is Heron Therapeutics, Inc. (HRTX) The Hot Biotech Stock Under $5?March 26 at 5:23 PM | insidermonkey.comRichmond Brothers Inc. Has $983,000 Stock Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX)Richmond Brothers Inc. increased its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 25.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 642,339 sharesMarch 20, 2025 | marketbeat.comTejara Capital Ltd Has $7.13 Million Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX)Tejara Capital Ltd reduced its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 12.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,661,547 shares of the biotechnology company's stock after sellinMarch 19, 2025 | marketbeat.comMonaco Asset Management SAM Sells 465,674 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)Monaco Asset Management SAM decreased its position in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 27.7% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,212,743 shares of the biotechnology company's stock after selling 465,674 shares duringMarch 15, 2025 | marketbeat.comCM Management LLC Has $1.07 Million Stock Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)CM Management LLC raised its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 40.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 700,000 shares of the biotechnology company's stock after purchasing an additional 200,000 sharesMarch 9, 2025 | marketbeat.comHeron Therapeutics (HRTX) to Release Quarterly Earnings on TuesdayHeron Therapeutics (NASDAQ:HRTX) will be releasing earnings before the market opens on Tuesday, March 11, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=666518)March 9, 2025 | marketbeat.comHeron Therapeutics: Four Horse Race Of Approved TherapiesMarch 8, 2025 | seekingalpha.comHeron Therapeutics (NASDAQ:HRTX) Downgraded by StockNews.com to HoldStockNews.com lowered Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday.March 8, 2025 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Stock Position Decreased by Los Angeles Capital Management LLCLos Angeles Capital Management LLC decreased its position in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 69.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 67,653 shares of the biotechnology company'sMarch 6, 2025 | marketbeat.comHeron Therapeutics (HRTX) to Release Earnings on TuesdayHeron Therapeutics (NASDAQ:HRTX) will be releasing earnings before the market opens on Tuesday, March 11, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=666518)March 4, 2025 | marketbeat.comBrokers Offer Predictions for HRTX Q1 EarningsHeron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Investment analysts at Northland Capmk issued their Q1 2025 EPS estimates for Heron Therapeutics in a research note issued to investors on Thursday, February 27th. Northland Capmk analyst C. Byrnes forecasts that the biotechnology company wilMarch 3, 2025 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Just Reported Earnings, And Analysts Cut Their Target PriceMarch 2, 2025 | finance.yahoo.comHeron Therapeutics (NASDAQ:HRTX) Upgraded to Buy at StockNews.comStockNews.com upgraded shares of Heron Therapeutics from a "hold" rating to a "buy" rating in a research report on Friday.March 1, 2025 | marketbeat.comHeron Therapeutics' (HRTX) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and issued a $4.00 price target on shares of Heron Therapeutics in a research note on Friday.March 1, 2025 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Issues Earnings Results, Beats Expectations By $0.05 EPSHeron Therapeutics (NASDAQ:HRTX - Get Free Report) issued its earnings results on Thursday. The biotechnology company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.05.February 28, 2025 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Announces Quarterly Earnings Results, Beats Estimates By $0.05 EPSHeron Therapeutics (NASDAQ:HRTX - Get Free Report) issued its quarterly earnings data on Thursday. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.03) by $0.05.February 28, 2025 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) shareholders are up 19% this past week, but still in the red over the last five yearsFebruary 28, 2025 | uk.finance.yahoo.comHeron Therapeutics Inc (HRTX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...February 28, 2025 | finance.yahoo.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by D.A. Davidson & CO.D.A. Davidson & CO. decreased its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 82.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 37,000 shares of the biotechnology company'sFebruary 28, 2025 | marketbeat.comHeron Therapeutics reports Q4 EPS 2c vs (7c) last yearFebruary 27, 2025 | markets.businessinsider.comHeron Therapeutics sees FY25 revenue $153M-$163M, consensus $160.63MFebruary 27, 2025 | markets.businessinsider.comHeron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate UpdatesFebruary 27, 2025 | prnewswire.comHeron Therapeutics IncFebruary 26, 2025 | money.usnews.comHeron Therapeutics (HRTX) to Release Quarterly Earnings on ThursdayHeron Therapeutics (NASDAQ:HRTX) will be releasing earnings before the market opens on Thursday, February 27, Financial Modeling Prep reports.February 21, 2025 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Stock Price Passes Above Two Hundred Day Moving Average - Should You Sell?Heron Therapeutics (NASDAQ:HRTX) Shares Cross Above 200 Day Moving Average - Should You Sell?February 15, 2025 | marketbeat.comHeron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025February 13, 2025 | prnewswire.comAccomplished CEO eyes another success story in CaryFebruary 13, 2025 | bizjournals.comHeron Therapeutics (NASDAQ:HRTX) Share Price Crosses Above 200 Day Moving Average - Here's What HappenedHeron Therapeutics (NASDAQ:HRTX) Share Price Passes Above Two Hundred Day Moving Average - Here's What HappenedFebruary 7, 2025 | marketbeat.comJPMorgan Chase & Co. Has $411,000 Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX)JPMorgan Chase & Co. boosted its position in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 295.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 206,711 shares of the biotechnology company's stock after purchasingJanuary 30, 2025 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Stock Rating Lowered by StockNews.comStockNews.com lowered Heron Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday.January 29, 2025 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) is a favorite amongst institutional investors who own 58%January 21, 2025 | finance.yahoo.comCongress Park Capital LLC Acquires 477,417 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)Congress Park Capital LLC lifted its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 24.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,455,495 shares ofJanuary 17, 2025 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Downgraded to "Hold" Rating by StockNews.comStockNews.com downgraded shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday.January 13, 2025 | marketbeat.comFranklin Resources Inc. Sells 6,304,716 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)Franklin Resources Inc. lowered its holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 99.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,026 shares of the biotechnology company's stoJanuary 3, 2025 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Sees Large Growth in Short InterestHeron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 29,980,000 shares, an increase of 8.9% from the November 30th total of 27,540,000 shares. Based on an average trading volume of 3,110,000 shares, the short-interest ratio is currently 9.6 days.January 1, 2025 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Rating Lowered to "Hold" at StockNews.comStockNews.com downgraded shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Tuesday.December 31, 2024 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by State Street CorpState Street Corp decreased its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 39.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,192,436 shares of the biotechnology company's stock after selling 2,088,December 29, 2024 | marketbeat.comCalifornia public company relocates to North CarolinaDecember 27, 2024 | bizjournals.comSan Diego Biotech Firm Heron Therapeutics Shifts Operations to North CarolinaDecember 27, 2024 | msn.comHeron Therapeutics relocates corporate headquarters to Cary, North CarolinaDecember 23, 2024 | markets.businessinsider.comHeron Therapeutics Announces Corporate Headquarters Relocation to Cary, North CarolinaDecember 23, 2024 | prnewswire.comHeron Therapeutics (NASDAQ:HRTX) Rating Increased to Buy at StockNews.comStockNews.com raised shares of Heron Therapeutics from a "hold" rating to a "buy" rating in a research report on Wednesday.December 11, 2024 | marketbeat.comHeron Therapeutics Secures Revenue Stream with Court Ruling, Analyst Recommends BuyDecember 5, 2024 | markets.businessinsider.comHeron Therapeutics (NASDAQ:HRTX) Stock, Insider Trading ActivityDecember 5, 2024 | benzinga.comHeron Therapeutics patent victory removes ‘major overhang,’ says NorthlandDecember 5, 2024 | markets.businessinsider.comRelief For Heron Therapeutics After The Court Win On CinvantiDecember 4, 2024 | seekingalpha.comHeron Therapeutics’ patent of Cinvanti found valid by Delaware District CourtDecember 4, 2024 | markets.businessinsider.comU.S. District Court Upholds Validity of CINVANTI® PatentsDecember 3, 2024 | prnewswire.comHeron Therapeutics: Approved Therapy With Blockbuster Potential But Meager RevenuesNovember 30, 2024 | seekingalpha.comHeron Therapeutics (NASDAQ:HRTX) Downgraded by StockNews.com to "Hold"StockNews.com lowered shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday.November 21, 2024 | marketbeat.com Remove Ads Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address HRTX Media Mentions By Week HRTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HRTX News Sentiment▼1.730.78▲Average Medical News Sentiment HRTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HRTX Articles This Week▼22▲HRTX Articles Average Week Remove Ads Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ANI Pharmaceuticals News Today Dyne Therapeutics News Today Indivior News Today Amphastar Pharmaceuticals News Today 89bio News Today Adaptive Biotechnologies News Today Evotec News Today ARS Pharmaceuticals News Today Ardelyx News Today Ocular Therapeutix News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HRTX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HRTX Stock Free HRTX Stock Alerts